Birchview Capital LP raised its stake in ContraFect Corporation (NASDAQ:CFRX) by 56.5% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,135,082 shares of the biotechnology company’s stock after acquiring an additional 410,000 shares during the quarter. ContraFect Corporation makes up 0.7% of Birchview Capital LP’s portfolio, making the stock its 11th biggest holding. Birchview Capital LP owned approximately 1.54% of ContraFect Corporation worth $1,260,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, White Pine Capital LLC raised its holdings in shares of ContraFect Corporation by 0.3% in the second quarter. White Pine Capital LLC now owns 253,870 shares of the biotechnology company’s stock worth $368,000 after acquiring an additional 825 shares during the last quarter. Hedge funds and other institutional investors own 24.45% of the company’s stock.

Shares of ContraFect Corporation (NASDAQ:CFRX) traded down $0.01 during trading hours on Wednesday, hitting $1.01. The stock had a trading volume of 66,945 shares, compared to its average volume of 52,783. ContraFect Corporation has a twelve month low of $0.80 and a twelve month high of $2.70.

ContraFect Corporation (NASDAQ:CFRX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. analysts expect that ContraFect Corporation will post -0.43 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Birchview Capital LP Has $1.26 Million Stake in ContraFect Corporation (CFRX)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at

About ContraFect Corporation

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Institutional Ownership by Quarter for ContraFect Corporation (NASDAQ:CFRX)

Receive News & Stock Ratings for ContraFect Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect Corporation and related stocks with our FREE daily email newsletter.